Active Ingredient History
Pidilizumab is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 1)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)
Hepatitis C, Chronic (Phase 1/Phase 2)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 2)
Ovarian Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue